Peter is responsible for the leadership of the Board, ensuring its effectiveness and setting its agenda. Peter held a number of senior positions in his 21 years with SmithKline-Beecham, including Chairman of Consumer Healthcare and President of Worldwide Supply Operations.
He has previously held Non-executive or Chairman roles at a number of public and private companies including Domino Printing Sciences plc, Glenmorangie plc and Genetix Group plc.
Committee Appointments
Audit and Risk Committee
Nomination Committee (Chairman)
Manuel has been CEO of Allergy Therapeutics plc since 2009, shaping strategy and driving growth. Prior to this, Manuel was the Principal Consultant for Biohealth LLC and CEO of International Operations of the Weinstein family’s group of companies.
External Appointments
None
Committee Appointments
None
Shaun was appointed as the Group's Chief Financial Officer (CFO) in August 2023, having previously served as Group Financial Controller since April 2022.
He brings significant financial experience, having held senior finance roles within blue-chip companies across multiple sectors, including Legal & General, Hastings Direct, Volution Group and American Express. Shaun is a Fellow of the Institute of Chartered Accountants in England and Wales and holds a PhD in polymer chemistry from the University of Sussex.
External Appointments
None
Committee Appointments
None
Cheryl has broad and deep global commercial experience in the biopharmaceutical sector. Trained as a pharmacist, during her 30-year tenure with GSK, Cheryl held senior executive positions in Canada, the US and Europe with responsibility for P&L, strategy and operations across numerous therapy areas including Allergy, Respiratory, Vaccines and HIV.
External Appointments
None
Committee Appointments
Remuneration Committee (Chair)
Audit and Risk Committee
Nomination Committee
Tunde is currently the Chief Medical Officer of Veloxis Pharmaceuticals in North Carolina, USA since August 2020. Prior to Veloxis he was Senior Vice President and Chief Medical Officer at Mallinckrodt Pharmaceuticals. His career includes leadership roles at Boehringer Ingelheim Pharmaceutical Inc. and the US Food and Drug Administration (“FDA”). Tunde is a physician trained in Pulmonary and Critical Care Medicine.
External Appointments
Veloxis Pharmaceutics, Inc
Committees Appointments
Nomination Committee
Remuneration Committee
Anthony is the Southern Fox nominated Director on our Board. He has worked in investment banking and fund management for over thirty years and, as Founder and Partner of Beagle Partners LLP, which advises Southern Fox, has managed or advised on multiple UK innovation technology investments. Anthony is Founder and Chairman of Argonaute RNA Ltd, a UK-based research company developing safe and reliable methods of temporarily silencing target genes in different tissue cells. Prior to this, Anthony held senior roles at ING Barings and was an equity analyst for Cazenove & Co. He holds an Investment Management Certificate from the Institute of Investment Management and Research.
External Appointments
Argonaute RNA Limited
Bristol Bluegreen Limited
Beagle Partners LLP
CBDerma Technology Limited
Inverpharma Limited
Las Lilas Limit
Rosemont Wildwall Ltd
Committee Appointments
Audit and Risk Committee
Simon is the nominated director of ZQ Capital. He founded the investment and advisory firm, ZQ Capital, in 2015. Prior to that Simon spent more than a decade as an investment banker advising international companies on their capital markets activities. He was Managing Director and Head of China Financial Institutions Group at Barclays from 2011 to 2015, following earlier roles at Goldman Sachs, Lehman Brothers and McKinsey & Company. He has a BA in mathematics and economics from Wesleyan University.
External Appointments
ECC HK Holdings Limited
Fortune Yacht Limited
KFM Kingdom Holdings Limited
Nu Skin Enterprises, Inc.
Sky Venture Partners LP
Skygem Acquisition Limited
Skygem Global Limited
Skygem International Holdings Limited
Skygem Investment Limited
Skygem UK Holding Limited
ZQ Capital Hong Kong Holdings Ltd
ZQ Capital Hong Kong Limited
ZQ Capital Limited
ZQ Capital Management Limited
ZQ Capital Services Limited
ZQ Evergreen Partners LP
ZQ Partners Ltd
ZQ Skygem Investors LP
Z-Trans Technology Company Limited
Committee Appointments
Remuneration Committee
David is a chartered accountant with over 25 years’ experience in financial markets, including 15 years as an equity portfolio manager and partner with Tudor Investment Corporation. He currently holds Non-Executive Director positions on the Boards of DeepForm, Argonaute RNA and Brainomix.
External Appointments
DeepForm
Argonaute RNA
Brainomix
Committee Appointments
Audit and Risk Committee (Chairman)